RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies
Briefings in Bioinformatics · 2024
DOI: 10.1093/bib/bbae328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, 2024. Verfasst von Aleksandr Ianevski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland. Hauptthemen laut MEDLINE: Drug Repositioning, Machine Learning. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Academy of Finland, Norwegian Health Authority South-East, Cancer Society of Finland.
Abstract (Originalsprache)
RepurposeDrugs (https://repurposedrugs.org/) is a comprehensive web-portal that combines a unique drug indication database with a machine learning (ML) predictor to discover new drug-indication associations for approved as well as investigational mono and combination therapies. The platform provides detailed information on treatment status, disease indications and clinical trials across 25 indication categories, including neoplasms and cardiovascular conditions. The current version comprises 4314 compounds (approved, terminated or investigational) and 161 drug combinations linked to 1756 indications/conditions, totaling 28 148 drug–disease pairs. By leveraging data on both approved and failed indications, RepurposeDrugs provides ML-based predictions for the approval potential of new drug–disease indications, both for mono- and combinatorial therapies, demonstrating high predictive accuracy in cross-validation. The validity of the ML predictor is validated through a number of real-world case studies, demonstrating its predictive power to accurately identify repurposing candidates with a high likelihood of future approval. To our knowledge, RepurposeDrugs web-portal is the first integrative database and ML-based predictor for interactive exploration and prediction of both single-drug and combination approval likelihood across indications. Given its broad coverage of indication areas and therapeutic options, we expect it accelerates many future drug repurposing projects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Finland.
- iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital, Finland.
- Faculty of Pharmacy, University of Helsinki, Finland.
- Drug Discovery and Chemical Biology (DDCB) consortium, Biocenter Finland.
- Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Norway.
- Oslo Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Norway.
ORCID-Profile: Tero Aittokallio, Ziaurrehman Tanoli
Förderung
- Academy of Finland
- Norwegian Health Authority South-East
- Cancer Society of Finland
- Sigrid Jusélius Foundation
- REMEDi4ALL
- European Union's Horizon Europe Research & Innovation
- European Union’s Horizon Europe Research & Innovation
Zitieren
APA
Ianevski, A., Kushnir, A., Nader, K., Miihkinen, M., Xhaard, H., Aittokallio, T., & Tanoli, Z. (2024). RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bbae328
Vancouver
Ianevski A, Kushnir A, Nader K, Miihkinen M, Xhaard H, Aittokallio T, et al. RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies. Briefings in Bioinformatics. 2024. doi:10.1093/bib/bbae328
BibTeX
@article{Ianevski2024,
author = {Ianevski, Aleksandr and Kushnir, Aleksandr and Nader, Kristen and Miihkinen, Mitro and Xhaard, Henri and Aittokallio, Tero and Tanoli, Ziaurrehman},
title = {RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono- and combination therapies},
journal = {Briefings in Bioinformatics},
year = {2024},
doi = {10.1093/bib/bbae328}
}
EUVIMED